Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDM

17.11.25 08:00 Uhr

Werte in diesem Artikel

NEW YORK, Nov. 17, 2025 /PRNewswire/ --

Rosen Law Firm Logo (PRNewsfoto/THE ROSEN LAW FIRM, P. A.)

Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. (NASDAQ: TNDM) resulting from allegations that Tandem Diabetes Care may have issued materially misleading business information to the investing public.

So What: If you purchased Tandem Diabetes Care securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=19024https://rosenlegal.com/submit-form/?case_id=41168or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.

What is this about: On August 7, 2025, before the market opened, the company issued a press release entitled "Tandem Diabetes Care Issues Voluntary Medical Device Correction for Select t:slim X2 Insulin Pumps." The release stated that Tandem Diabetes had "announced a voluntary medical device correction for select t:slim X2 insulin pumps to address a potential speaker-related issue that can trigger an error resulting in a discontinuation of insulin delivery."

On this news, Tandem Diabetes' stock fell 19.9% on August 7, 2025.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions.  Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      case@rosenlegal.com
      www.rosenlegal.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/rosen-law-firm-encourages-tandem-diabetes-care-inc-investors-to-inquire-about-securities-class-action-investigation--tndm-302616600.html

SOURCE THE ROSEN LAW FIRM, P. A.

In eigener Sache

Übrigens: Tandem Diabetes Care und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf Tandem Diabetes Care

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Tandem Diabetes Care

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Tandem Diabetes Care Inc Registered Shs

Wer­bung

Analysen zu Tandem Diabetes Care Inc Registered Shs

DatumRatingAnalyst
08.03.2019Tandem Diabetes Care OutperformBMO Capital Markets
27.02.2019Tandem Diabetes Care BuyLake Street
26.09.2018Tandem Diabetes Care BuyDougherty & Company LLC
14.09.2018Tandem Diabetes Care NeutralRobert W. Baird & Co. Incorporated
24.08.2018Tandem Diabetes Care BuyDougherty & Company LLC
DatumRatingAnalyst
08.03.2019Tandem Diabetes Care OutperformBMO Capital Markets
27.02.2019Tandem Diabetes Care BuyLake Street
26.09.2018Tandem Diabetes Care BuyDougherty & Company LLC
24.08.2018Tandem Diabetes Care BuyDougherty & Company LLC
22.08.2018Tandem Diabetes Care HoldStifel, Nicolaus & Co., Inc.
DatumRatingAnalyst
14.09.2018Tandem Diabetes Care NeutralRobert W. Baird & Co. Incorporated
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Tandem Diabetes Care Inc Registered Shs nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen